Swedbank AB Sells 2,109 Shares of IDEXX Laboratories, Inc. $IDXX

Swedbank AB lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,853 shares of the company’s stock after selling 2,109 shares during the period. Swedbank AB’s holdings in IDEXX Laboratories were worth $20,145,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter valued at $3,666,459,000. J. Stern & Co. LLP increased its stake in IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in IDEXX Laboratories by 63,503.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after purchasing an additional 1,442,174 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock valued at $527,162,000 after purchasing an additional 592,834 shares during the period. Finally, Norges Bank bought a new position in shares of IDEXX Laboratories during the 4th quarter worth about $332,265,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 25th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Finally, UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $558.60 on Friday. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The stock has a market cap of $44.06 billion, a price-to-earnings ratio of 41.13, a PEG ratio of 3.04 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm’s 50-day simple moving average is $554.89 and its 200 day simple moving average is $604.73.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.